corresponds to the timing of subsequent the cycles have 3 assessment of months. response to A omalizumab correction was as specified in employed. its marketing authorisation. After the first The marketing 16-week cycle, authorisation the for Response omalizumab omalizumab to cohort is recommends omalizumab divided into that omalizumab responders responders and revert to
subsequent cycles have 3 months. A correction was employed. corresponds to the timing of the assessment of response to omalizumab as specified in its marketing authorisation. Response to omalizumab After the first 16-week cycle, the omalizumab cohort is divided into omalizumab responders and responders The marketing authorisation for omalizumab recommends that revert to